TransCode Therapeutics secures $20 million financing

TransCode Therapeutics has entered into a financing agreement that could provide up to $20 million. This funding is crucial for advancing the company's innovative drug delivery platform, particularly its lead candidate TTX-siPNA, which targets various cancers. The agreement signifies investor confidence in TransCode's technology and its potential to address unmet needs in oncology. This capital infusion will support ongoing research and development efforts, including clinical trials, and further solidify the company's position in the biopharmaceutical landscape.